- Home
- TOVX vs OGEN Comparison
TOVX vs OGEN Comparison
Compare TOVX & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- OGEN
- Stock Information
- Founded
- TOVX 2001
- OGEN 1996
- Country
- TOVX United States
- OGEN United States
- Employees
- TOVX N/A
- OGEN N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- OGEN Health Care
- Exchange
- TOVX Nasdaq
- OGEN Nasdaq
- Market Cap
- TOVX 3.6M
- OGEN 4.6M
- IPO Year
- TOVX 2006
- OGEN N/A
- Fundamental
- Price
- TOVX $0.64
- OGEN $0.18
- Analyst Decision
- TOVX Hold
- OGEN
- Analyst Count
- TOVX 1
- OGEN 0
- Target Price
- TOVX N/A
- OGEN N/A
- AVG Volume (30 Days)
- TOVX 2.4M
- OGEN 223.6K
- Earning Date
- TOVX 05-20-2025
- OGEN 05-19-2025
- Dividend Yield
- TOVX N/A
- OGEN N/A
- EPS Growth
- TOVX N/A
- OGEN N/A
- EPS
- TOVX N/A
- OGEN N/A
- Revenue
- TOVX N/A
- OGEN N/A
- Revenue This Year
- TOVX N/A
- OGEN N/A
- Revenue Next Year
- TOVX N/A
- OGEN N/A
- P/E Ratio
- TOVX N/A
- OGEN N/A
- Revenue Growth
- TOVX N/A
- OGEN N/A
- 52 Week Low
- TOVX $0.74
- OGEN $0.16
- 52 Week High
- TOVX $12.25
- OGEN $3.43
- Technical
- Relative Strength Index (RSI)
- TOVX 23.36
- OGEN 42.40
- Support Level
- TOVX $1.32
- OGEN $0.16
- Resistance Level
- TOVX $1.45
- OGEN $0.21
- Average True Range (ATR)
- TOVX 0.14
- OGEN 0.01
- MACD
- TOVX -0.07
- OGEN 0.00
- Stochastic Oscillator
- TOVX 2.92
- OGEN 40.00
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.